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Abstract
Emergence of antibiotic resistance due to New Delhi Metallo β-lactamase (NDM-1)
bacterial enzymes is of great concern due to their ability to hydrolyze wide range of
antibiotics. Efforts are ongoing to obtain the atomistic details of the hydrolysis mech-
anism in order to develop novel drugs and inhibitors against NDM-1. Especially, it
remains elusive how drug molecules of different family of antibiotics are hydrolyzed
by NDM-1 in an efficient manner. Here we report the detailed molecular mecha-
nism of NDM-1 catalyzed hydrolysis of cephalexin, a cephalosporin family drug, and
meropenem, a carbapenem family drug. This study employs molecular dynamics (MD)
simulations using hybrid quantum mechanical/molecular mechanical (QM/MM) meth-
ods at the density functional theory level, based on which reaction pathways and the
associated free energies are obtained. We find that the mechanism and the free energy
barrier for the ring–opening step are the same for both the drug molecules, while the
subsequent protonation step differs. In particular, we observe that the mechanism of
the protonation step depends on the R2 group of the drug molecule. Our simulations
show that allylic carbon protonation occurs in the case of cephalexin drug molecule
where Lys211 is the proton donor and the proton transfer occurs via a water chain
formed (only) at the ring–opened intermediate structure. Based on the free energy
profiles, the overall kinetics of the drug hydrolysis is discussed. Finally, we show that
the proposed mechanisms and free energy profiles could explain various experimental
observations.
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Introduction
Escalating antimicrobial resistance (AMR) has been realized as a global threat to the public
health in the recent times.1 AMR related death is estimated to be about 700 000 per year
and it is predicted to be the biggest devastating problem by 2050 with 10 million deaths per
year.2 Implementation of effective measures to combat drug resistance shown by bacteria,
in particular, development of novel antimicrobial drugs, has to be expedited. One of the
ways in which bacteria develop antibiotic resistance is by expressing β–lactamase enzymes,
which catalyze the hydrolysis of antibiotic drug molecules in an efficient way. New Delhi
Metallo-β-lactamase-1 (NDM-1) is one such enzymes which was identified only in 2009,3
however becoming widely expressed in bacteria causing hospital–acquired and community–
acquired infections.4 Of great concern, NDM-1 carrying bacteria are known to hydrolyze
nearly all the clinically used β–lactam antibiotics including penicillins, cephalosporins and
even carbapenems considered as the last resort drugs.5–8 Thus there is an urgent need to
develop effective inhibitors for NDM-1 so that life threatening infections due to NDM-1
carrying “superbugs” be cured.
Development of inhibitors is majorly aided by the knowledge of structure and reactivity of
the active site. Over the last few decades a number of crystallographic,9–12 spectroscopic,13–24
and computational11,25–32 studies have reported which shed light on the molecular structure
and catalytic reactions of di–Zn metallo β−lactamases (MBLs), including NDM-1. Active
site of NDM-1 has two Zn(II) binding sites bridged with a hydroxide (W1). The Zn1 site
is coordinated with His120, His122, and His189, while the Zn2 site is bound to Asp124,
Cys208, and His250. The existence of a water molecule bound to Zn2 in the apoenzyme is
also debated.33
Based on the existing studies on NDM-1 and other di–Zn Class B1 MBLs,33–35 the hy-
drolysis is initialized by the nucleophilic attack (ES → EI) where the bridging hydroxide
attacks the β–lactam ring of the drug molecules (see Figure 1). This leads to the intermedi-
ate structure EI where the β–lactam N of the ring–opened drug molecule is bound to Zn2.
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Figure 1: (a) General mechanism of NDM-1 catalyzed β–lactam antibiotic hydrolysis. Chem-
ical structure of cephalexin (b) and meropenem (c). R1 and R2 groups are shown in blue
and in red, respectively.
The subsequent step involves a proton transfer to N3 (or C5) and is followed by decoordina-
tion of the drug from the active site, completing the hydrolysis; see Figure 1 for the atom
numbers followed. However, the detailed mechanism of hydrolysis is not fully understood.
Mostly, the proton donor has to be identified and the mechanism of proton transfer has to be
ascertained. Further, the rate–determining step of the whole process has to be established.
In general, proton transfer to N3 is anticipated, while C5 protonation has been also noticed
in some experimental studies.9,18 A tautomerization where C4–C5 double bond is migrated
to N3–C4 could result in protonation of C5 instead of N3, and was noted in the experiments
by Tioni et al.18 while studying the carbapenem hydrolysis by BcII MBL. Protonation of
C5 protonation was observed in the crystal structure of ring–opened cephalexin bound to
NDM-1.9 Thus, both N3 and C5 are identified as the likely proton acceptors during EI →
EP reaction. The factors controlling the protonation mechanism are yet to be scrutinized.
Asp124 bound to Zn2 was proposed to get protonated during the nucleophilic attack of the
bridging hydroxyl group in NDM-125,32 and other MBLs.27,28 Thus the protonated Asp124
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formed after the nucleophilic attack could act as the proton donor.36 However, detailed
mutational studies indicate that Asp124 is not likely to be involved in the protonation of
the intermediate.16,36,37 The same conclusion was also arrived by the QM/MM MD study
of meropenem hydrolysis by NDM-1.32 The bridging hydroxyl group was proposed as the
proton donor by Zhang and Hao based on the crystal structure of ampicillin complexed
with NDM-1.10 Observation of water or hydroxyl group bound to the Zn ions in the crystal
structures of the reaction intermediates12 also hints that protonation might occur from the
dissociation of the bulk water coordinating to the Zn site during the hydrolysis reaction.
This mechanism was also supported by the previous QM/MM MD simulation, where a bulk
water coordinates to Zn1 in the EI structure, which subsequently dissociate to protonate
N3.
32
Formation of anionic intermediate is also reported based on various spectroscopic data for
di–Zn MBLs13,18,21,23,24,38 and further supported by QM/MM simulations.25,27,28,30,32 X–ray
structures of di–Zn MBLs with ring–opened drug molecules have N3–Zn2 coordination, thus
these structures are likely to be the “trapped” EI intermediate state.9,10,12,18,39,40 Spectro-
scopic and kinetic data of NDM-1 catalyzed hydrolysis of chromacef and nitrocefin suggest
that the rate constant for EI → EP (k3) is nearly 10 times smaller than ES → EI (k2)
hinting on the accumulation of the anionic intermediate.23,24 Based on the kinetic parame-
ters derived from these experiments, it was concluded that the rate determining step is the
protonation of the anionic intermediate (i.e. EI → EP ). This is also consistent with the
kinetic studies where solvent isotope effect was observed in the hydrolysis of various drug
molecules by di–Zn MBLs.13,16,41 Previous QM/MM study also agrees with the formation of
stable anionic intermediate, where the negative charge of β–lactam N is stabilized by Zn2.32
The predicted mechanism from QM/MM MD simulation is composed of a water diffusion
towards the active site after the formation of the EI complex.32 The diffused water molecule
coordinates with Zn1, which subsequently acts as the proton donor. However, coordination
of a bulk water molecule is anticipated to be a slow process in the complexed structure,
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and thus an alternative mechanism was proposed for di–Zn MBLs by Vila and co–workers
where the apoenzyme active site is considered to be composed of Zn2 coordinated with
a additional water molecule (W2).33 According to this mechanism, the proton transfer to
the anionic intermediate occurs directly from W2. Klein and co–workers have carried out
QM/MM MD simulation of CCrA catalyzed hydrolysis using this active site model and
found that accumulation of anionic species doesn’t occur since proton transfer to N3 occurs
spontaneous with the formation of EI.26 Based on this a pre–coordinated water model can
excluded as accumulation of anionic species is observed in various experiments. Further,
crystallographic structures was found without any bulk water molecules coordinated at the
Zn sites in the trapped reaction intermediate states.12
In this work, we investigate various mechanistic routes for cephalexin and meropenem hy-
drolysis catalyzed by NDM-1. Primarily, we address the question of N3 protonation versus C5
protonation. First principle density functional theory (DFT) based QM/MM Car-Parrinello
MD42 combined with conventional43,44 and the recently developed well–sliced metadynam-
ics45 approaches are used here for simulating chemical reactions and to obtain free energy
barriers.
Methods and Models
We followed a three step simulation strategy in this work. At first, we carried out MM
force–field MD simulations of the fully solvated protein–drug complexes ES of cephalexin
and meropenem. This was followed by DFT based QM/MM MD simulations to further
equilibrate these systems. Finally, taking the equilibrated structures, we performed QM/MM
metadynamics or well–sliced metadynamics simulations to model chemical reactions. The
reaction mechanism and free energy barriers of all elementary steps are obtained from these
simulations.
Henry–Michaelis complexes of NDM-1 with cephalexin and meropenem were built from
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the crystal structures of NDM-1 complex with hydrolyzed drug molecules, PDB IDs 4RL29
and 4EYL,12 respectively. Restrained Electrostatic Potential (RESP) derived point charges
of the drug molecules were computed using the R.E.D tools46 (see SI) and the potentials for
the drug molecules were described by the GAFF force–field.47 The protonation states for all
the ionizable residues of the protein were set to that correspond to pH= 7. We considered
Asp124 in the deprotonated form, as found in our earlier study.48 All the crystal structure
water molecules were retained while building the initial structure. Two Zn atoms are bridged
by a hydroxyl, and the Zn1 site is coordinated with His120, His122, and His189, whereas the
Zn2 site is bound to Asp124, Cys208, and His250; see SI Figure S1. Zn–ligand coordination
was modeled following the work of Suarez et al.31 While modeling the cephalexin–NDM-1
complex three Na+ ions were added to neutralize the whole system which was solvated with
8914 water molecules in a periodic box of dimensions 66×75×76 A˚3. In order to model the
solvated meropenem–NDM-1 complex, we added four Na+ ions to the system containing the
protein in a periodic box of 70×68×72 A˚3 containing 7990 water molecules. The parm9949
version of the AMBER force field was used to model the protein. MM water molecules were
treated using the TIP3P50 force field. The particle-mesh Ewald method51 was employed to
compute the long range electrostatics, and a non-bonded interaction cutoff of 15 A˚ was used.
Sander module of the AMBER program package was used to perform MM MD simula-
tions.52 These MD simulations were carried out with a time step of 1 fs. All the atoms in
the system, including the solvent molecules were relaxed during the MD simulations. We
performed nearly 2 ns NPT simulation at 1 atm and 300 K using Berendsen barostat53 and
Langevin thermostat54 in order to obtain the equilibrium density. With the equilibrated
cells, we carried out 10 ns of NV T MD simulations. These simulations were carried out till
the RMSD fluctuations of the backbone and the active sites have converged satisfactorily;
see SI Figure S3.
Hybrid QM/MM simulations42,55–57 of the equilibrated structures obtained from the MM
simulations were performed using the CPMD/GROMOS interface, as available in the CPMD
7
package.58 In these simulations, the whole drug molecule, two Zn ions, the embedded hy-
droxide and the coordinated side chains of His120, His122, Asp124, His189, Cys208, His250,
were treated quantum mechanically; see SI Figure S2. Additionally, one water molecule
(W2) was also treated quantum mechanically when modeling EI1 → EI2 reaction, while
the side chain of Lys211 as well as two water molecules (W3 and W4) were described quan-
tum mechanically for modeling EI1 → EI2′ reaction; see SI Figure S4(b). We used capping
hydrogen atoms to saturate the dangling chemical bonds of the QM part. Capping hydrogen
atoms were placed between the Cβ–Cγ bonds in His120, His122, His189 and His250, between
the Cα–Cβ bonds in Asp124 and Cys208 and between Cδ–C bond in Lys211 (SI Figure S2).
A cubic QM box with a side length of 27.5 A˚ was used, and the QM subsystems were treated
at the DFT level using the PBE59 density functional and ultra soft pseudopotentials were
used to describe the core–potentials.60 Plane wave basis set with a plane wave cutoff of 25 Ry
was used in these calculations. The QM/MM electrostatic coupling was treated using the
scheme by Laio et al.42 The QM/MM MD runs were carried out using the Car-Parrinello
method with a time step of 0.125 fs and a fictitious mass of 700 a.u. for the orbital degrees of
freedom.57,61 The nuclear and the orbital degrees of freedom were thermostated using Nose´-
Hoover chains thermostats.62 Ionic temperature in the MD simulations was set to 300 K.
We carried out NV T QM/MM MD simulations for nearly 10 ps for both the systems, before
starting metadynamics simulations.
In order to accelerate the sampling of chemical reactions, thus to obtain reaction mecha-
nism and free energy barriers, we used the metadynamics method.43,63–66 By applying dynam-
ically grown biasing potentials, metadynamics technique enhances the sampling of a selected
set of collective variables (CVs) that are relevant for a chemical reaction. We employed the
extended Lagrangian variant of metadynamics,44 and the details of the metadynamics sim-
ulation setup and the choice of CVs for various elementary steps of the hydrolysis reaction
can be found in SI Section 8. We also used the well–sliced metadynamics approach,45 for
exploring broad and unbound free energy surfaces by a combination of umbrella sampling
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and metadynamics techniques. Initial structures of metadynamics simulations were taken
from the equilibrated structures obtained from QM/MM NV T runs.
The transition state for the step ES→EI was obtained through committer analysis67 ;
see Section SI 10. Accuracy of the free energy estimates, considering the typical errors due
to metadynamics and the density functional is about (W+1) kcal mol−1, where W is the
height of the Gaussian potentials used in metadynamics; see Section SI 11.
Results and Discussion
In order to study the hydrolysis of cephalexin, first we equilibrated the ES structure using
MM, QM/MM MD simulations (see SI Figure S1 and SI Section 4) and then we explored five
different reaction pathways using a series of metadynamics simulations (see SI Table S3).
The Path 1, which we investigated first, is ES → EI1 → EI2 → EI3 → EP; see Fig-
ure 2. This pathway is identical to that we proposed in our earlier study on meropenem
hydrolysis.32 The elementary reaction steps were explored using independent metadynamics
simulations, and based on which, free energy barriers for the elementary steps were com-
puted; see Figure 3. The first step ES → EI1 involves the ring–opening reaction where the
bridging OW1 attacks C2. Most importantly, in the ES structure, Zn1 and Zn2 are only
weakly coordinated to O1 and O9, respectively, while these interactions strengthen as the
OW1· · ·Zn2 coordination interaction is weakened. Hydrogen bonding interaction between
HW1 and Asp124:Oδ1 is favorably orienting W1 for the nucleophilic attack on C2. Subse-
quently, OW1 attacks C2, and C2–N3 bond is cleaved. Almost simultaneous with C2–N3 bond
breakage, we observed coordination of N3 to Zn2, Zn2–Asp124:Oδ2 bond dissociation, and
HW1 transfer from OW1 to Asp124:Oδ1; see SI Figure S20. It is interesting to note that
these processes were occurring almost simultaneously near the transition state. For further
verification we characterized the transition state for ES→ EI1 reaction through committor
analysis and the structure of the transition state is shown in SI Figure S8(a). In the transi-
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Figure 2: Mechanistic paths of cephalexin hydrolysis by NDM-1 explored in our QM/MM–
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are hypothesized steps on the basis of our simulation. See SI Figure S23 for the mechanistic
routes investigated for meropenem hydrolysis.
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tion state, C2–N3 distance is 1.58 A˚, and OW1–C2 distance is 1.51 A˚. Of great importance,
we notice that HW1 is delocalized between OW1 and Asp124:Oδ1 in the transition state struc-
ture. According to the computed free energy profile in Figure 3, we find that the free energy
barrier for ES→EI1 (20 kcal mol−1; see SI Figure S9) was found to be smaller than the
reverse step EI1→ES (32 kcal mol−1; see SI Figure S10)
In the EI1 structure, a bulk water molecule (W2) is located near the hydrophilic pocket
consisting of the C4 carboxylate, Lys211, and backbone amide hydrogen of Asn220; see
SI Figure S4(b). EI1 → EI2 composes of diffusion of W2 (which was treated quantum
mechanically in this simulation), followed by coordination to Zn1 and the associated decoor-
dination of O1 and OW1 from Zn1; see SI Figure S5. The free energy barriers for EI1→ EI2
and for the reverse step were computed as 25 kcal mol−1 (SI Figure S11) and 11 kcal mol−1
(SI Figure S12), respectively.
EI2 → EI3 is the N3 protonation step. While modeling this step, we sampled two pro-
tonation pathways in the same simulation: (a) protonation by the transfer of HW1 protons,
which are coordinated to Asp124:Oδ1 and OW1; (b) protonation by the transfer of HW2 pro-
tons of the W2 water molecule coordinated to Zn1. However, we have found that transfer of
HW2 to N3 is the preferred route for N3 protonation. The free energy barrier for this reaction
was computed as 9 kcal mol−1 (SI Figure S13). With the formation of EI3, the hydroxyl
bridge is reformed as in the ES structure, yet Asp124:Oδ1 is protonated and Asp124:Oδ2 is
weakly bound to the Zn2 site. Thus we modeled EI3 → EP, where we sampled the coor-
dination of Asp124:Oδ2 and decoordination of O9 from the Zn2 site. Here we observed the
product (EP) formation, where the HW1 is first transferred to OW1 from Asp124:Oδ1, and
Asp124:Oδ2 coordinates to Zn2. This process is also synchronous with the decoordination
of O9 from Zn2. The free energy barrier for this reaction was computed as 10 kcal mol
−1
(SI Figure S14).
Having determined the mechanism and free energy profile along Path 1, we modeled the
reaction along Path 2, where the reaction proceeds through ES→ EI1→ EI4; see Figure 2.
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Here, we explored the possibility of protonation of N3 in EI1, before the water diffusion to the
active site, through a direct proton transfer from W1 to N3. This is motivated by the work
of Zhang and Hao, who proposed this mechanism based on the close distance between OW1
and N3 in the crystal structure PDB ID 3Q6X.
10 In our simulation, we observed the proton
transfer to N3 from Asp124:Oδ1. The free energy barrier for this reaction was computed to
be 36 kcal mol−1 (SI Figure S15). Thus it is clear that Path 1 is preferred over Path 2; see
Figure 3).
Subsequently, we explored ES→ EI1→ EI2′ → EI3′ →EP, i. e. Path 3; see Figure 2.
Along this pathway, we investigated the possibility of C5 protonation. On our careful analysis
of the equilibrated EI1 structure, we observed that a water molecule (W3) is in the vicinity
of C5. Interestingly, W3 is hydrogen bonded to another water molecule (W4), which in turn
is hydrogen bonded to protonated Lys211; see SI Figure S4(b). Thus we explored proton
transfer to C5 from Lys211 through W3 and W4. Tautomerization of the double bond from
C4–C5 to C4–N3 in the six membered ring should also take place during this reaction. We
successfully simulated this reaction, and found that the free energy barrier for EI1 → EI2′
is 13 kcal mol−1 (SI Figures S16 and S22). Free energy profiles for Path 1 and Path 3
(Figure 3) indicate that cephalexin hydrolysis proceeds preferably through C5 protonation
along Path 3, rather than via N3 protonation along Path 1, since the former has a smaller
free energy barrier for protonation. We hypothesize that, EI2′ further results in EP′ after
the coordination of a bulk water molecule to the active site as in EI1→ EI2 along Path 1.
The crystal structures of the hydrolyzed cephalexin bound to NDM-1 reported by Feng et
al.9 where C5 is in tetrahedral coordination also embeds an oxygen atom between the two
Zn ions. On the other hand, the observation of C5 protonation in Tioni et al.
18 experiment
is anticipated to be due to tautomerization of the product after the release, instead of
protonation by Lys211 since their experiments were conducted with cephalosporins having
large R2 groups.
As next, we investigated the 1,3–proton shift occurring from N3 to C5 in EI3, i.e. ES→
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EI1→ EI2→ EI3→ EI4′ (Path 4); see Figure 2. In that simulation, we explicitly sampled
the tautomerization of double bond in the six membered ring of the drug molecule, how-
ever, no 1,3–proton shift was observed even after applying a bias potential of 30 kcal mol−1
(SI Figure S18). Thus, we excluded the possibility that Path 4 is a preferred reaction
pathway.
Another pathway which we studied was Path 5, i.e. ES → EI1 → EI5, where proton
transfer from the protonated Lys211 occurs to N3 (instead of C5 as in Path 3) , through W3
and W4 water molecules; see Figure 2. However, this reaction was not observed, even after
applying a bias potential of 30 kcal mol−1 (SI Figure S19). Thus we conclude that Path 3
is the preferred protonation pathway compared to Path 5.
As next we revisited meropenem hydrolysis mechanism which we carried in our previous
work.32 In particular, we performed computations of all elementary steps along Path 1 and
Path 3 using the same procedures used for studying cephalexin hydrolysis, as before. see
Figure 3 and SI Section 17. Along Path 1 the free energy profile has qualitatively the same
feature as that for cephalexin. The free energy barrier for ES→EI1 along Path 1 was also
computed to be identical (20 kcal mol−1) for both cephalexin and meropenem. However,
in the EI1 structure corresponding to meropenem, a water chain connecting Lys211 to C5
was absent unlike in the case of cephalexin. Thus, we exclude the possibility of Path 3 in
the case of meropenem. The origin of this difference between meropenem and cephalexin
could be ascribed to the differences in the R2 groups of these drug molecules. Clearly,
cephalexin has a small R2 group compared to that for meropenem; see Figure 1. Our analysis
indicates that the bulky R2 group of meropenem could result in large steric effect such that
it blocks the formation of stable water chain connecting Lys211 and C5. This is evident
from Figure 4(a), where the number of water molecules surrounding the allylic C5 atom is
plotted, obtained by integrating the corresponding radial distribution function computed
along the canonical ensemble trajectory of the EI1 structure. In the case of cephalexin,
there are two water molecules within 4 A˚ of C5, while this is nearly zero for meropenem. The
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overlapped structures of EI1 with meropenem and cephlaxin in Figure 4(b), also indicates
that position of W3 in cephalexin is occupied by the five membered ring part of the R2 group
of meropenem. Thus, our study leads to the conclusion that depending on the bulkiness of
the R2 group, the protonation mechanism could change.
We compared the equilibrated structures of the intermediates observed along Path 1
and Path 3 with the available X-ray structures; see SI Section 9. Strikingly, the crystal
structure of NDM-1 with ring–opened cephalexin (PDB ID 4RL29) has significant similarity
with the EI2′ structure; see SI Figure S7 and SI Table S5. In particular, we find that the
orientation of the proton at the C5 position is identical with the crystal structure. Thus, the
crystal structure is more likely to be EI3′ state, where Zn1 has a bound water molecule (via
EI2′ →EI3′). This is a strong support for the proposed mechanism of protonation of C5
from Lys211. Additionally, the intermediate EI1 found in our study along the meropenem
hydrolysis pathway matches very well with the crystal structure PDB ID 4EYL;12 see SI Fig-
ure S7 and SI Table S6. It is worth noting that no water molecules are bound to Zn1 and
Zn2 in this crystal structure, thus confirming our proposed mechanism that the coordination
of a bulk water molecule occurs after the formation of EI1. The crystal structure of NDM-1
with ampicillin (PDB ID: 3Q6X10) having Zn1 bound water is likely to represent either EI2
or EI3. Such excellent agreements with the crystal structural data support the proposed
reaction pathways in our study.
If reaction pathways Path 1 and Path 3 is casted to the following enzymatic reaction
model
E + S
k1
k−1
ES
k2
EI1
k3
E + P
then
kcat =
k2k3
k2 + k3
. (1)
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In this model, we consider that k3 is the effective rate constant for the decay of EI1, which
includes proton transfer to the substrate, water coordination to the active site, and prod-
uct decoordination. Since EI1 → E + P involves water coordination from the bulk, and
the barrier for this process is higher than that for the other elementary steps, we arrive
at kcat ≈ k3. In the kinetic experiments by Yang et al.,23,24 the authors have found that
kcat ≈ k3 for NDM-1 catalyzed hydrolysis of nitrocefin and chromacef molecules. Thus the
experimental data is in line with our studies. Further, both their experiment and our pro-
posed mechanism supports the accumulation of anionic intermediates. kcat values measured
for various cephalosporins and carbapenems catalyzed by NDM-1 and BcII enzymes do not
vary much (which is only an order of magnitude).3,68 This is consistent with our conclusion
that kcat ≈ k3. We also predict that solvent isotope effects will influence kcat as EI1→E+P
involves water coordination and deprotonation. This is consistent with the observation of
solvent isotope effects in the experiments by Vila and co–workers.16
Conclusion
We find that the detailed mechanism of hydrolyisis by the two drug molecules, namely
cephalexin and meropenem, are different. The ring–opening mechanism and the correspond-
ing free energy barriers are identical for both the drug molecules. However, the mechanism
of proton transfer steps for the two drug molecules differ. Protonation of the ring–opened
substrate could occur in two different ways. In one case, proton transfer occurs to the β–
lactam nitrogen of the ring–opened intermediate by a water molecule which diffuses into the
active site after the ring–opening reaction. Along the other route, proton transfer occurs
from Lys211 to C5 through a chain of two water molecules. The latter mechanism would take
place when the drug molecules contain small R2 group as in the case of cephalexin, while the
former mechanism is active for drug molecules such as meropenem having a larger R2 group.
Observation of different protonation pathways also agree well with the crystal structures of
16
the reaction intermediates involving cephalexin and meropenem. We conclude that kcat ≈ k3
and thus is determined mostly by the water coordination reaction that occurs prior to the
N3 protonation in the case of nitrocefin, while it takes place after the C5 protonation in
the case of cephalexin. This is also in agreement with various experimental kinetic studies.
The detailed mechanistic picture, especially the structural and energetic data, presented in
this work brings new molecular understanding on the catalytic reactions by NDM-1 and we
believe that these results will aid in the ongoing research towards developing novel drugs
and inhibitors targeting NDM-1.
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